Pangenomic Health Past Earnings Performance
Past criteria checks 0/6
Pangenomic Health's earnings have been declining at an average annual rate of -70.1%, while the Healthcare Services industry saw earnings growing at 5.7% annually.
Key information
-70.1%
Earnings growth rate
-44.1%
EPS growth rate
| Healthcare Services Industry Growth | -3.9% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pangenomic Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -12 | 2 | 0 |
| 30 Jun 23 | 0 | -12 | 3 | 0 |
| 31 Mar 23 | 0 | -12 | 3 | 1 |
| 31 Dec 22 | 0 | -12 | 3 | 1 |
| 30 Sep 22 | 0 | -5 | 2 | 1 |
| 30 Jun 22 | 0 | -4 | 2 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -3 | 1 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: NARA is currently unprofitable.
Growing Profit Margin: NARA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NARA is unprofitable, and losses have increased over the past 5 years at a rate of 70.1% per year.
Accelerating Growth: Unable to compare NARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NARA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).
Return on Equity
High ROE: NARA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.